Brokerages Set Agilon Health, Inc. (NYSE:AGL) Price Target at $86.18

Agilon Health, Inc. (NYSE:AGL) has received a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $91.30.

A number of brokerages recently commented on AGL. Wall Street Zen raised Agilon Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings lowered Agilon Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 27th. Wells Fargo & Company reissued an “overweight” rating and set a $146.00 price objective (up from $141.00) on shares of Agilon Health in a report on Tuesday, August 11th. JPMorgan Chase & Co. downgraded shares of Agilon Health from a “neutral” rating to an “underweight” rating and set a $21.00 price objective for the company. in a research report on Monday, May 4th. Finally, Jefferies Financial Group upgraded Agilon Health from a “hold” rating to a “buy” rating and boosted their price objective for the company from $27.50 to $48.00 in a research report on Thursday, May 7th.

Hedge Funds Weigh In On Agilon Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGL. Proficio Capital Partners LLC purchased a new stake in Agilon Health in the second quarter valued at approximately $210,000. Rubicon Founders LLC acquired a new position in Agilon Health during the second quarter worth $11,290,448,000. Great Lakes Advisors LLC acquired a new position in Agilon Health during the second quarter worth $702,000. Bank of New York Mellon Corp lifted its holdings in Agilon Health by 9.5% during the second quarter. Bank of New York Mellon Corp now owns 35,336 shares of the company’s stock valued at $3,787,000 after purchasing an additional 3,074 shares in the last quarter. Finally, Alpine Global Management LLC purchased a new position in Agilon Health during the fourth quarter valued at $84,000.

Agilon Health Stock Up 3.9%

Shares of NYSE AGL opened at $96.32 on Monday. The business has a 50-day moving average of $105.84 and a 200-day moving average of $60.88. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -6.75 and a beta of 3.01. Agilon Health has a 12 month low of $7.48 and a 12 month high of $133.04.

Agilon Health (NYSE:AGL) last released its earnings results on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.90. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%.The company had revenue of $1.49 billion during the quarter, compared to the consensus estimate of $1.45 billion. Sell-side analysts expect that Agilon Health will post -2.95 earnings per share for the current fiscal year.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.